Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000196025 | SCV000250073 | benign | not specified | 2015-04-17 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV000755255 | SCV000262378 | benign | Hereditary hemorrhagic telangiectasia | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000196025 | SCV000302334 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Eurofins Ntd Llc |
RCV000196025 | SCV000340690 | benign | not specified | 2016-03-22 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000206022 | SCV000477325 | likely benign | Telangiectasia, hereditary hemorrhagic, type 1 | 2016-06-14 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000206022 | SCV000603448 | benign | Telangiectasia, hereditary hemorrhagic, type 1 | 2023-11-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000196025 | SCV001774482 | benign | not specified | 2021-07-08 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001795317 | SCV002498048 | benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | ENG: BP4, BP7, BS1, BS2 |
Ambry Genetics | RCV002381666 | SCV002696359 | benign | Cardiovascular phenotype | 2015-06-08 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Breakthrough Genomics, |
RCV001795317 | SCV005227518 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Genome Diagnostics Laboratory, |
RCV000196025 | SCV001809594 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics, |
RCV000196025 | SCV001917677 | benign | not specified | no assertion criteria provided | clinical testing | ||
Laboratory of Diagnostic Genome Analysis, |
RCV001795317 | SCV002036117 | likely benign | not provided | no assertion criteria provided | clinical testing |